Our Partnerships and Collaborations

We Are Better Together

At VBI, we believe that it takes the power of many great minds and organizations to solve the toughest challenges.

We value our partnerships with teams that share our philosophy and vision, and continue to seek meaningful collaborations across industry, government, and advocacy and patient groups.

brii biosciences
Brii Biosciences (Brii Bio)

VBI and Brii Bio have a license and collaboration agreement for the development of VBI-2601 (BRII-179) as part of a potential functional cure for chronic hepatitis B infection.

Read Press ReleaseArrow

gsk
GlaxoSmithKline (GSK)

VBI and GSK have a collaboration to clinically evaluate the combination of VBI-1901, VBI’s cancer vaccine immunotherapeutic candidate, with GSK’s proprietary AS01 adjuvant system in patients with recurrent glioblastoma (GBM).

Read Press ReleaseArrow

canada
Government of Canada

Through their Strategic Innovation Fund, the Government of Canada awarded VBI up to a CAD $56 million contribution to support the development of the Company’s prophylactic coronavirus vaccine candidates, VBI-2901 and VBI-2902, through Phase 2 clinical studies.

Read Press ReleaseArrow

National_Research Council of Canada
National Research Council of Canada (NRC)

VBI and the NRC have a collaboration to develop a COVID-19 vaccine candidate and a pan-coronavirus vaccine candidate, targeting COVID-19, severe acute respiratory syndrome (SARS), and Middle East respiratory syndrome (MERS). This is the latest collaboration in a series of collaborations with the NRC, which have included research and development on a number of preclinical programs.

Read Press ReleaseArrow

resilience Logo
Resilience Biotechnologies, Inc. (Resilience)

(previously Therapure Biopharma Inc.)

VBI and Resilience have an agreement for the development and manufacturing services in preparation for production of its coronavirus vaccine candidates. The collaboration is expected to support clinical studies through Phase 2 clinical development.


syneos health
Syneos Health (Syneos)

VBI and Syneos Health have a partnership for commercialization of VBI’s 3-antigen prophylactic hepatitis B vaccine candidate in the United States, Europe, and Canada, pending regulatory approvals.

Read Press ReleaseArrow

man woman talking

Contact Us

We are always seeking meaningful and innovative partnerships to prevent or treat disease.

If you are interested in learning more about a potential collaboration with us, please contact us at:

partner@vbivaccines.com

Go top